ARIAD Announces Ponatinib Presentations at Annual American Society of Hematology Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec 3, 2012 - ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the presentations on ponatinib, its investigational BCR-ABL inhibitor, that will take place at the 54th Annual Meeting of the American Society of Hematology (ASH) being held in Atlanta, December 8 to 11, 2012. Updated and new results on the PACE trial will be featured in five presentations – two oral and three posters.
| PACE
Trial: 12-Month Follow Up in Chronic Phase Patients
|
||
| Title: | A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial | |
| Oral Session: | 632. Chronic Myeloid Leukemia - Therapy I Session | |
| Date & Time: | Sunday, December 9, 2012, 4:30 p.m. | |
| Abstract No.: | 163 | |
| Presenter: | Jorge E. Cortes, M.D.
(The University of Texas MD Anderson Cancer Center)
|
|
| Location: | Georgia World Congress Center, A411-A412 | |
| PACE
Trial: Efficacy and Safety in Advanced Phase Patients
|
||
| Title: | Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial | |
| Oral Session: | 632. Chronic Myeloid Leukemia - Therapy II Session | |
| Date and Time: | Tuesday, December 11, 2012 at 8:00 a.m. | |
| Abstract No.: | 915 | |
| Presenter: | Hagop M. Kantarjian, M.D. (The University of Texas MD Anderson Cancer Center) | |
| Location: | Georgia World Congress Center, A411-A412 | |
| PACE
Trial: Results According to Prior Tyrosine Kinase Inhibitor
Therapy
|
||
| Title: | Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP?CML): Results from the PACE Trial | |
| Poster Session: | 632. Chronic Myeloid Leukemia - Therapy: Poster III | |
| Date & Time: | Monday, December 10, 2012, 6:00 – 8:00 p.m. | |
| Abstract No.: | 3749 | |
| Presenter: | Dong-Wook Kim, M.D., Ph.D. (Mary's Hospital, The Catholic University of Korea) | |
| Location: | Georgia World Congress Center, Hall B1-B2 | |
| PACE
Trial: Molecular Response Data
|
||
| Title: | Molecular Responses with Ponatinib in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia: Results From the PACE Trial | |
| Poster Session: | 632. Chronic Myeloid Leukemia - Therapy: Poster III | |
| Date & Time: | Monday, December 10, 2012, 6:00 – 8:00 p.m. | |
| Abstract No.: | 3763 | |
| Author: | Andreas Hochhaus, M.D., University Medical Center Jena in Germany | |
| Location: | Georgia World Congress Center, Hall B1-B2 | |
| PACE
Trial: Multivariate Analysis of Parameters
|
||
| Title: | Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome?Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial | |
| Poster Session: | 632. Chronic Myeloid Leukemia - Therapy: Poster III | |
| Date & Time: | Monday, December 10, 2012, 6:00 – 8:00 p.m. | |
| Abstract No.: | 3747 | |
| Presenter: | Michael Mauro, M.D. (Oregon Health & Science University) | |
| Location: | Georgia World Congress Center, Hall B1-B2 | |
| Phase 1
Trial: Long-term Results
|
||
| Title: | Long-Term Anti-Leukemic Activity of Ponatinib in Patients with Philadelphia Chromosome-Positive Leukemia: Updated Results from an Ongoing Phase 1 Study | |
| Poster Session: | 632. Chronic Myeloid Leukemia - Therapy: Poster III | |
| Date & Time: | Monday, December 10, 2012, 6:00 – 8:00 p.m. | |
| Abstract No.: | 3743 | |
| Presenter: | Michael Deininger, M.D., Ph.D. (University of Utah School of Medicine Huntsman Cancer Institute) | |
| Location: | Georgia World Congress Center, Hall B1-B2 | |
ARIAD Pharmaceuticals, Inc. is an emerging global oncology company focused on the discovery, development and commercialization of medicines to transform the lives of cancer patients. ARIAD's approach to structure-based drug design has led to several internally discovered, molecularly targeted medicines for drug-resistant or difficult-to-treat cancers, including chronic myeloid leukemia and non-small cell lung cancer. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).
Contact: ARIAD Pharmaceuticals, Inc.
For Investors
Kendra Adams, 617-503-7028
Kendra.adams@ariad.com
or
For Media
Liza Heapes, 617-621-2315
Liza.heapes@ariad.com
Posted: December 2012
